Literature DB >> 15809670

The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer.

L Klotz1, A Correia, W Zhang.   

Abstract

OBJECTIVE: To determine whether the duration of the off-treatment interval in patients being treated with intermittent androgen deprivation therapy can be predicted by the length of the CAG trinucleotide repeat polymorphism in the androgen receptor.
METHODS: This is a companion study to a prospective randomized trial, NCIC CTG PR-7, comparing intermittent to continuous androgen deprivation therapy in men with PSA progression after radiation therapy. The duration of the first off-treatment interval was established for 76 participants randomized to the intermittent therapy arm of the trial. Androgen receptor CAG repeat polymorphism lengths were determined for these 76 participants. Statistical analysis was completed to determine a relationship between CAG repeat length and the duration of the off-treatment interval.
RESULTS: A significant correlation was not established (P = 0.424) between androgen receptor CAG repeat length and the duration of the first off-treatment interval. Categorical analysis of CAG repeat lengths using 18 and 22 as cutoff points did not find any significant difference in the mean duration of the off-treatment interval between categories (P = 0.672 and 0.774, respectively).
CONCLUSION: No relationship was established between the duration of the first off-treatment interval and the CAG repeat length.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15809670     DOI: 10.1038/sj.pcan.4500792

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  3 in total

1.  Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer.

Authors:  Chia-Cheng Yu; Shu-Pin Huang; Yung-Chin Lee; Chao-Yuan Huang; Chia-Chu Liu; Tzyh-Chyuan Hour; Chun-Nung Huang; Bang-Jau You; Ta-Yuan Chang; Chun-Hsiung Huang; Bo-Ying Bao
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

Review 2.  Intermittent versus continuous androgen suppression for prostatic cancer.

Authors:  P D Conti; A N Atallah; H Arruda; B G O Soares; R P El Dib; T J Wilt
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

3.  Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy.

Authors:  John M Pendleton; Winston W Tan; Satoshi Anai; Myron Chang; Wei Hou; Kathleen T Shiverick; Charles J Rosser
Journal:  BMC Cancer       Date:  2008-05-11       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.